Depression treatment for Highland Beach — measurement-based, 12 minutes away.

RECO Health's Delray Beach campus sits twelve minutes north of Highland Beach along A1A — close enough for Bel Lido Isle or Toscana residents to attend PHP or IOP without relocating. What that seven-mile drive buys is clinical density: in-house psychiatry, measurement-based pharmacology anchored to PHQ-9, protocolized CBT, Behavioral Activation, and IPT, plus on-site rTMS and IV ketamine for treatment-resistant depression. Every plan begins with a DSM-5-TR diagnostic formulation and a documented escalation pathway — not a monotherapy SSRI and a follow-up in six weeks.

Highland Beach occupies the narrow oceanfront corridor between Delray Beach and Boca Raton, and A1A puts residents of Bel Lido Isle, Toscana, and Boca Cove roughly twelve minutes from RECO Health’s Delray campus. For someone whose depression has outlasted a first SSRI trial from a Boca primary-care office, that seven-mile drive buys access to a clinical density most general behavioral-health practices in southern Palm Beach County cannot offer: PHP and IOP staffed by in-house psychiatry, protocolized psychotherapy, and — when indicated — depression treatment that includes rTMS and IV ketamine under one roof.

Diagnostic formulation and severity staging

The initial evaluation is not a symptom checklist. A psychiatrist works through a DSM-5-TR differential that distinguishes major depressive disorder from persistent depressive disorder, bipolar II depression, adjustment disorder with depressed mood, and depression secondary to a general medical condition or substance use. Mood charting and a careful family history are used to screen for hypomania a client might not spontaneously report — a common miss that turns a monotherapy SSRI into an iatrogenic mixed state.

Severity is anchored numerically. The PHQ-9 quantifies depressive load at intake and at every subsequent touchpoint; the Columbia Suicide Severity Rating Scale (C-SSRS) formalizes suicide-risk stratification; GAD-7 captures the anxiety comorbidity that appears in most depression presentations. Baseline labs — TSH with reflex free T4, B12, folate, vitamin D, CBC, and metabolic panel — rule out hypothyroidism, anemia, and vitamin deficiencies that mimic or worsen depressive symptoms before pharmacology is committed to.

Level of care is then matched to the data. PHP (roughly 30 clinical hours per week) is indicated for severe presentations, active suicidal ideation with plan, or functional collapse; IOP (nine to twelve hours per week) fits moderate severity where the client remains employable or in school. The decision is written into the treatment plan alongside the specific PHQ-9 and C-SSRS scores that support it, so that step-down criteria are equally explicit.

Pharmacology sequenced by evidence, not habit

First-line pharmacotherapy for major depressive disorder is an SSRI — sertraline or escitalopram in most cases — or an SNRI such as venlafaxine or duloxetine when a comorbid pain or fatigue presentation argues for noradrenergic coverage. Doses are titrated to therapeutic range, not stopped at a starter dose, and response is judged at four to six weeks against a repeat PHQ-9. Bupropion is reserved for clients where sexual side effects, weight, or fatigue dominate the side-effect calculus, and mirtazapine for insomnia with appetite loss.

Partial responders — a PHQ-9 drop of 20 to 50 percent — are augmented before they are switched. Evidence-supported augmentation options include aripiprazole (2 to 5 mg), quetiapine XR, lithium at therapeutic serum level, or bupropion added to an SSRI. A wholesale switch to a second monotherapy is reserved for non-responders and for clients whose side effects preclude titration. Every medication change is documented against the PHQ-9 trajectory rather than against clinical impression alone.

Treatment-resistant depression is defined by two failed adequate trials, not by clinician frustration. When that threshold is met, RECO’s psychiatrists move to interventional options rather than cycling a fifth antidepressant. Buspirone augmentation, thyroid hormone (T3) augmentation, and MAOI trials remain available where clinically indicated, but the default pathway for TRD becomes neuromodulation.

Behavioral therapy modalities with evidence for depression

Therapy at RECO is protocolized, not eclectic. Cognitive Behavioral Therapy for depression targets the cognitive distortions and automatic thoughts that maintain low mood, using thought records, activity scheduling, and behavioral experiments in the sequence established by Beck. Behavioral Activation — the modality with the strongest independent effect size for severe depression — restores rewarding and mastery activities through structured monitoring rather than motivation alone.

Interpersonal Therapy (IPT) is offered when depression is anchored to grief, role transition, interpersonal disputes, or interpersonal deficits — presentations where CBT alone tends to underperform. For clients whose depression is trauma-linked, Cognitive Processing Therapy or EMDR is layered in, because untreated PTSD is one of the most reliable drivers of antidepressant non-response. Acceptance and Commitment Therapy (ACT) supports values-based behavior change when rumination and experiential avoidance dominate the clinical picture.

Group programming is not filler. DBT skills groups — mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness — are indicated for depression with emotion dysregulation or self-harm history, and Motivational Interviewing frames the co-occurring substance-use work that a meaningful proportion of RECO’s depression clients also need.

Escalation pathway when medication and therapy aren’t enough

Roughly a third of clients with major depressive disorder fail to reach remission after two adequate antidepressant trials. RECO’s escalation pathway is defined before that point is reached, so that treatment-resistant clients are not left to drift. Repetitive transcranial magnetic stimulation (rTMS) — 10 Hz stimulation over the left dorsolateral prefrontal cortex at 120% of resting motor threshold, 3,000 pulses per session, across the standard 36-session FDA-cleared protocol — is offered on-site for insurance-eligible TRD.

IV ketamine (0.5 mg/kg over 40 minutes, six-infusion induction with maintenance dosing scheduled by response) is used where suicidality or occupational collapse means the client does not have six weeks to wait for an SSRI to work. Esketamine (Spravato) is available where a REMS-monitored intranasal protocol is clinically or logistically preferred, with the two-hour post-dose observation that the REMS program requires.

Escalation is not a last resort — it is a planned step. Each interventional option is discussed at the treatment-planning stage, so that a client who does not respond to two SSRI trials moves to rTMS or ketamine on a calendar, not after months of drift.

What to expect on the first visit from Highland Beach

Admissions from Highland Beach typically begin with a phone call and a same-day or next-day intake appointment at the Delray campus. The first visit runs 90 to 120 minutes and includes a psychiatric evaluation, PHQ-9, GAD-7, C-SSRS, ASRS if adult attentional symptoms are reported, and a substance-use screen. Labs are drawn on-site or ordered to the client’s PCP.

By the end of the intake, the client leaves with a written diagnostic formulation, a level-of-care recommendation (PHP versus IOP), a proposed pharmacology plan with specific agent and dose, and a therapy schedule. There is no waiting list for medication management — psychiatry sees clients within the first week of admission.

For clients who arrive already on an antidepressant prescribed by a primary-care physician in Boca or Delray, that regimen is continued or adjusted at intake rather than discontinued abruptly. Records from prior providers — pharmacy history, past prescriber notes, prior PHQ-9 scores where available — are integrated into the diagnostic formulation so that RECO does not repeat trials the client has already run and failed.

Insurance and admissions from Highland Beach

RECO Health is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS commercial plans, and admissions staff verify benefits, deductibles, and PHP/IOP session limits before the first appointment. For Highland Beach residents, that verification is typically completed the same day the initial call comes in, and the twelve-minute drive along A1A means no relocation, no residential stay, and no interruption to family or work obligations for outpatient levels of care.

Coverage for interventional depression treatment — rTMS and esketamine — carries a separate prior-authorization pathway, and admissions manages that submission directly with the payer once TRD criteria are documented in the chart. Self-pay pricing is available for IV ketamine and for clients whose plans do not participate, and both figures are quoted transparently before scheduling rather than surfaced at billing.

Serving residents of: Bel Lido Isle, Boca Cove, Ocean Cove, Toscana, Penthouse.